Review
Biochemistry & Molecular Biology
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh
Summary: The management of castration-resistant prostate cancer has seen significant progress, with three novel hormonal agents showing survival benefits in non-metastatic patients and a wider range of management options being investigated for metastatic disease.
Article
Cell Biology
Qing Li, Fanfei Kong, Rong Cong, Jian Ma, Cuicui Wang, Xiaoxin Ma
Summary: PVT1 is highly expressed in endometrial cancer and cancer stem cells (CSCs) and correlates with poor prognosis. It promotes the malignant behavior and stemness of endometrial cancer cells (ECCs) and CSCs. In contrast, miR-136, which is lowly expressed, has the opposite effect. PVT1 competitively sponges miR-136 to activate Sox2, which promotes the malignant behavior and stemness of ECCs and CSCs. Simultaneously downregulating PVT1 and upregulating miR-136 has the strongest anti-tumor effect in endometrial cancer.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Fayola Levine, Olorunseun O. Ogunwobi
Summary: The study reveals that PVT1 exon 9 plays a role in regulating claudin 4 expression and migration, particularly in claudin-low triple negative breast cancer, suggesting potential clinical implications.
Review
Pharmacology & Pharmacy
Maoping Cai, Xian-Lu Song, Xin-An Li, Mingkun Chen, Jiading Guo, Dong Hua Yang, Zhanghui Chen, Shan-Chao Zhao
Summary: Castration-resistant prostate cancer (CRPC), especially metastatic CRPC (mCRPC), is a common and deadly malignancy in men worldwide. The natural or acquired drug resistance of CRPC makes clinical treatment challenging. Understanding the mechanisms of drug resistance in mCRPC is essential for developing effective therapeutic strategies. This review focuses on new insights in mCRPC treatment and discusses the mechanisms governing resistance to new drugs, such as taxanes, androgen receptor signaling inhibitors (ARSIs), and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). Strategies to overcome drug resistance based on these mechanisms are also discussed.
DRUG RESISTANCE UPDATES
(2023)
Article
Cardiac & Cardiovascular Systems
Kanae Hasegawa, Hideaki Ito, Kenichi Kaseno, Shinsuke Miyazaki, Yuichiro Shiomi, Naoto Tama, Hiroyuki Ikeda, Kentaro Ishida, Hiroyasu Uzui, Seiko Ohno, Minoru Horie, Osamu Yokoyama, Hiroshi Tada
Summary: Medical castration can prolong QT/QTc intervals in prostate cancer patients, and may cause TdP/VFs even in patients without risk of QT prolongation before therapy. An increase in QTc interval >50 ms from baseline could be a predictor of TdP/VF. Close attention to QTc interval throughout medical castration is crucial in preventing malignant arrhythmias.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Oncology
Vicenc Ruiz de Porras, Albert Font, Alvaro Aytes
Summary: Taxanes are currently the most active chemotherapy drugs used in the treatment of mCRPC, but resistance easily develops, limiting long-term survival. Platinum-based treatments, in addition to taxanes, are the limited therapeutic options for patients progressing to taxanes. Therefore, further research on the role of platinum-based chemotherapy in mCRPC and the identification of predictive biomarkers are urgently needed.
Article
Medicine, Research & Experimental
Ao Liu, Yi Gao, Qi Wang, Wenhao Lin, Zhiyang Ma, Xiaoqun Yang, Lu Chen, Danfeng Xu
Summary: This study collected pre- and post-ADT tumor samples from five Chinese patients with advanced prostate cancer and analyzed their whole-exome sequencing, tumor heterogeneity, and clonal evolution pattern. The results showed significant changes in the gene mutation pattern and heterogeneity after androgen deprivation therapy.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Chemistry, Medicinal
Yujie Huang, You Zhai, Meijia Wu, Chengdong Chang, Jindan Luo, Dongsheng Hong, Qingwei Zhao, Yao Dai, Jian Liu
Summary: This study investigated the role of mTORC2 signaling in docetaxel-resistant prostate cells to find potential methods for clinical treatment. The expression of mTORC2 is crucial for docetaxel drug resistance in prostate cells. The mTORC1/2 inhibitor AZD8055 disrupts mTORC2 kinase activity more significantly than the mTORC1 inhibitor Rapamycin, leading to decreased docetaxel-mediated resistance. Therefore, reversing docetaxel resistance may become a therapeutic option for the treatment of metastatic castration-resistant prostate cancer patients.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Biochemistry & Molecular Biology
Tianhong Pan, Song-Chang Lin, Yu-Chen Lee, Guoyu Yu, Jian H. Song, Jing Pan, Mark Titus, Robert L. Satcher, Theocharis Panaretakis, Christopher Logothetis, Li-Yuan Yu-Lee, Sue-Hwa Lin
Summary: The study demonstrates that statins can reduce bone marrow adiposity and slow down the progression of prostate cancer in bones. By affecting the transition of BMSC to adipocytes, the progression of PCa may be delayed.
Article
Oncology
Junjiang Liu, Yunxia Zhang, Shoubin Li, Fuzhen Sun, Gang Wang, Dong Wei, Tao Yang, Shouyi Gu
Summary: Androgen deprivation therapy (ADT) can increase the expression of androgen receptor (AR) through amplification of chromosome X in prostate cancer. The overexpression of OPHN1, which is located in the same region as the AR gene, was found to promote cell survival, inhibit apoptosis, and enhance resistance to ADT, thereby facilitating prostate cancer progression.
Article
Biology
Meng Wu, Rongyu Zhang, Zixiong Zhang, Ning Zhang, Chenfan Li, Yongli Xie, Haoran Xia, Fangjiao Huang, Ruoying Zhang, Ming Liu, Xiaoyu Li, Shan Cen, Jinming Zhou
Summary: A bifunctional small molecule called Z15 was discovered and identified as an effective and selective androgen receptor (AR) antagonist and degrader. It interacts with the ligand-binding domain (LBD) and activation function-1 region of AR, promoting its degradation through the proteasome pathway. In vitro and in vivo studies showed that Z15 successfully suppressed AR, AR mutants, and AR splice variants (ARVs) transcription activity, overcoming resistance to second-generation antiandrogens (SGAs) induced by AR LBD mutations, amplification, and ARVs. This highlights the synergistic importance of AR antagonism and degradation in advanced prostate cancer treatment.
Article
Oncology
Lilin Wan, Yifan Liu, Ruiji Liu, Weipu Mao
Summary: This research identified GAD1 as a hub gene in the progression and development of drug resistance in prostate cancer. The expression of GAD1 was significantly correlated with clinicopathological features and the tumor immune microenvironment. This study provides new insights into prostate cancer drug resistance and offers potential immune-related therapeutic targets and biomarkers.
CANCER CELL INTERNATIONAL
(2023)
Article
Oncology
Frantzeska Giginis, Joshua Wang, Aaron Chavez, Manuela Martins-Green
Summary: Prostate Cancer (PCa) is the second most prevalent cancer in the world. Currently, most treatments for PCa involve Androgen Deprivation Therapy (ADT) which is not effective for metastatic Castration-Resistant Prostate Cancer (mCRPC). Decreasing the enzyme catalase, which reduces oxidative stress levels, has the potential to provide another target for Prostate Cancer therapy.
AMERICAN JOURNAL OF CANCER RESEARCH
(2023)
Article
Medicine, Research & Experimental
Gido Snaterse, Lisanne F. van Dessel, Job van Riet, Angela E. Taylor, Michelle van der Vlugt-Daane, Paul Hamberg, Ronald de Wit, Jenny A. Visser, Wiebke Arlt, Martijn P. Lolkema, Johannes Hofland
Summary: The study revealed that 11-ketotestosterone (11KT) is the most abundant circulating active androgen in patients with CRPC, constituting 60% of the total active androgen pool. Treatment with glucocorticoids significantly reduced 11KT and testosterone concentrations. The circulating active androgen concentrations were associated with a distinct intratumor gene expression signature.
Review
Pharmacology & Pharmacy
Yuanyuan Wang, Jiyuan Chen, Zhengjie Wu, Weihong Ding, Shen Gao, Yuan Gao, Chuanliang Xu
Summary: This review examines the emerging information on resistance mechanisms to enzalutamide in castration-resistant prostate cancer, including various signaling pathways and metabolic effects, and suggests potential therapeutic strategies for overcoming enzalutamide resistance.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Review
Oncology
Onayemi Titilayo Onagoruwa, Gargi Pal, Chika Ochu, Olorunseun O. Ogunwobi
FRONTIERS IN ONCOLOGY
(2020)
Article
Genetics & Heredity
Gargi Pal, Lia Di, Akintunde Orunmuyi, E. Oluwabunmi Olapade-Olaopa, Weigang Qiu, Olorunseun O. Ogunwobi
G3-GENES GENOMES GENETICS
(2020)
Article
Oncology
Fayola Levine, Olorunseun O. Ogunwobi
Summary: The study reveals that PVT1 exon 9 plays a role in regulating claudin 4 expression and migration, particularly in claudin-low triple negative breast cancer, suggesting potential clinical implications.
Article
Oncology
E. O. Asante-Asamani, Gargi Pal, Leslie Liu, Olorunseun O. Ogunwobi
Summary: Prostate cancer is the most commonly diagnosed solid organ cancer in men globally, and current diagnosis methods have limitations. The creation of a new composite score, Prostac, based on recently discovered PCa biomarkers, shows promise for improving PCa diagnosis accuracy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Ismaheel O. Lawal, Thabo Lengana, Gbenga O. Popoola, Akintunde T. Orunmuyi, Mankgopo M. Kgatle, Kgomotso M. G. Mokoala, Mike M. Sathekge
Summary: Ga-68-PSMA-11 PET/CT plays a crucial role in guiding salvage therapy for detecting prostate cancer recurrence, demonstrating a high lesion detection rate for biochemical recurrence in patients previously treated with primary local therapy. Risk of extra-pelvic recurrence increases with rising PSA levels.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Akintunde T. Orunmuyi, Sikiru A. Adebayo, Olayinka S. Ilesanmi, Augustine O. Takure, E. Oluwabunmi Olapade-Olaopa
Summary: This study analyzed the bone scan results of newly diagnosed prostate cancer patients in Nigeria and found a positive correlation between bone metastases and PSA levels and Gleason scores. No patients with PSA levels < 20 ng/mL and Gleason scores < 7 had bone metastases. The findings of this study are consistent with global reports.
NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Editorial Material
Oncology
Andrew J. Vickers, Brandon Mahal, Olorunseun O. Ogunwobi
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Clinical Neurology
Confidence Raymond, Michael T. Jurkiewicz, Akintunde Orunmuyi, Linshan Liu, Michael Oluwaseun Dada, Claes N. Ladefoged, Jarmo Teuho, Udunna C. Anazodo
Summary: This systematic review provides a consensus on the clinical feasibility of machine learning methods for brain PET attenuation correction. The performance of ML-AC was compared to clinical standards. The results suggest that ML-AC has acceptable performance for clinical PET imaging but further research is needed to assess its robustness and clinical implementation.
JOURNAL OF NEURORADIOLOGY
(2023)
Article
Public, Environmental & Occupational Health
Cicely K. Johnson, May May Leung, Grace X. X. Ma, Olorunseun O. Ogunwobi
Summary: This study investigated the participation rate of self-identified Black individuals in New York City in a study on the relationship between dietary practices and colorectal cancer screening behavior. The results showed that recruiting Black participants was not challenging, but individuals in Caribbean neighborhoods expressed mistrust and declined to participate, suggesting the need for further work to address this recruitment challenge.
JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES
(2023)
Letter
Oncology
Andrew J. Vickers, Brandon Mahal, Olorunseun O. Ogunwobi
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Fayola Levine, Emmanuel Asante-Asamani, Gargi Pal, Michael Liss, Olorunseun Ogunwobi
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2023)
Meeting Abstract
Oncology
Lin Zhu, Gargi Pal, Taylor Kazaoka, Rubia Shahbaz, Marsha Zibalese-Crawford, Sarah-Jane Dodd, Carolyn Y. Fang, Yin Tan, Grace X. Ma, Olorunseun O. Ogunwobi
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Medicine, General & Internal
Akinfemi Akingboye, Fahad Mahmood, Nabeel Amiruddin, Michael Reay, Peter Nightingale, Olorunseun O. Ogunwobi
Summary: Patients with active cancer have a threefold increase in risk of hospitalisation with COVID-19, and higher age, urea, and CRP levels are associated with increased mortality. Machine learning algorithm (MLA) shows potential in predicting outcomes of COVID-19 infection in cancer patients.
Meeting Abstract
Oncology
Gargi Pal, Emmanuel Asante-Asamani, Leslie Liu, Olorunseun O. Ogunwobi
Meeting Abstract
Oncology
Gargi Pal, Olorunseun Ogunwobi
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2020)